Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

AB Science will be granted a patent, valid through 2040, covering the medical use of masitinib as a treatment for sickle cell ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

Doctors and researchers at the University of Nebraska Medical Center are hoping to bring a different therapy that uses a ...

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL ...